Berubicin is an investigational anthracycline-like cytotoxic agent and topoisomerase II inhibitor primarily under study for the treatment of recurrent glioblastoma multiforme and other central nervous… Read more
Berubicin is an investigational anthracycline-like cytotoxic agent and topoisomerase II inhibitor primarily under study for the treatment of recurrent glioblastoma multiforme and other central nervous system malignancies due to its ability to cross the blood-brain barrier. To support rigorous pharmaceutical development and regulatory compliance, laboratories require high-quality reference standards of the parent compound, as well as its related metabolic breakdown products and process-related impurities. These materials are essential for accurate impurity profiling and the validation of analytical methods, such as liquid chromatography and mass spectrometry. Furthermore, stable isotope labelled compounds are indispensable in pharmacokinetic studies and quantitative analysis, serving as internal standards to account for matrix effects and ensure precise measurement of drug concentrations in biological matrices. By utilizing these specialized reference materials, researchers can maintain stringent quality control throughout the lifecycle of Berubicin formulations.